CAS No.112809-51-5,Letrozole Suppliers

Products Categories

Pharmaceutical (471)
Others (86)
Organic Chemicals (32)
Reagent (5)
Materials (4)
(2)
Basic Inorganic Chemicals (1)
Food Additives (1)
Plant Extract (1)

Basic Information

Molecular Structure:
CAS No.:	112809-51-5
Name:	Letrozole
Article Data:	34
Cas Database

Formula:	C₁₇H₁₁N₅
Molecular Weight:	285.308
Synonyms:	4,4'-(1H-1,2,4-Triazol-1-ylmethylene)bisbenzonitrile
EINECS:	675-034-8
Density:	1.21g/cm³
Melting Point:	100-102 °C
Boiling Point:	374.4 °C at 760 mmHg
Flash Point:	180.3 °C
Solubility:	N/A
Appearance:	white to off-whitecrystalline powder
Hazard Symbols:	Xi
Risk Codes:	36/37/38
Safety:	26-36
Transport Information:	N/A
PSA:	78.29000
LogP:	2.65916

Synthetic route

: 112809-26-4
4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile hydrochloride

: 1194-02-1
4-fluorobenzonitrile

: 112809-51-5
letrozol

Conditions

Conditions	Yield
Stage #1: 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile hydrochloride With potassium tert-butylate In N,N-dimethyl-formamide at -25 - -20℃; for 1.08333h; Inert atmosphere; Stage #2: 4-fluorobenzonitrile In N,N-dimethyl-formamide at -25 - -20℃; for 1.08333h;	98.6%
Stage #1: 4-(1H-1,2,4-triazol-1-ylmethyl)benzonitrile hydrochloride With potassium tert-butylate In N,N-dimethyl-formamide at -25 - -20℃; for 1.08333h; Stage #2: 4-fluorobenzonitrile In N,N-dimethyl-formamide at -25 - -20℃; for 1.08333h; Stage #3: With hydrogenchloride In water; N,N-dimethyl-formamide at -20 - 0℃; for 0.5h; pH=6.0 - 6.5; Product distribution / selectivity;	55%

: 288-88-0
1,2,4-Triazole

: 935477-95-5
toluene-4-sulfonic acid bis-(4-cyano-phenyl)-methyl ester

: 112809-51-5
letrozol

Conditions

Conditions	Yield
Stage #1: 1,2,4-Triazole With tetrabutylammomium bromide; potassium carbonate In water; 4-methyl-2-pentanone for 2h; Stage #2: toluene-4-sulfonic acid bis-(4-cyano-phenyl)-methyl ester In water; 4-methyl-2-pentanone at 20 - 30℃; for 48h; Stage #3: With hydrogenchloride In water; 4-methyl-2-pentanone for 1h;	97.42%

: potassium cyanide

: 1-(bis(4-bromophenyl)methyl)-1H-1,2,4-triazole

: 112809-51-5
letrozol

Conditions

Conditions	Yield
Stage #1: potassium cyanide With acetic acid In ethylene glycol Sealed tube; Stage #2: 1-(bis(4-bromophenyl)methyl)-1H-1,2,4-triazole With P(t-Bu)3 Palladacycle Gen. 3; potassium acetate In 1,4-dioxane; water at 60℃; for 16h; Concentration; Sealed tube;	97%

: 4-((4-cyanophenyl)(1H-1,2,4-triazol-1-yl)methyl)benzamide

: 112809-51-5
letrozol

Conditions

Conditions	Yield
With trifluoroacetic anhydride In 1,4-dioxane at 0 - 20℃; for 1h;	90%

: 584-13-4
4-amino-1,2,4-triazole

: 69545-39-7
4,4'-dicyanodiphenylbromomethane

: 112809-51-5
letrozol

Conditions

Conditions	Yield
Stage #1: 4-amino-1,2,4-triazole; 4,4'-dicyanodiphenylbromomethane In acetonitrile for 24h; Reflux; Stage #2: With hydrogenchloride; sodium nitrite In water; acetonitrile at 0 - 5℃; for 6h; Solvent; Time;	88.7%

: potassiumhexacyanoferrate(II) trihydrate

: 1-(bis(4-bromophenyl)methyl)-1H-1,2,4-triazole

: 112809-51-5
letrozol

Conditions

Conditions	Yield
With sodium carbonate In water; N,N-dimethyl-formamide at 120℃; for 24h;	87%

: zinc cyanide

: 1-(bis(4-bromophenyl)methyl)-1H-1,2,4-triazole

: 112809-51-5
letrozol

Conditions

Conditions	Yield
With 1,1'-bis-(diphenylphosphino)ferrocene; water; bis(dibenzylideneacetone)-palladium(0) In N,N-dimethyl-formamide at 120℃; for 15h; Inert atmosphere;	86%

: 1194-02-1
4-fluorobenzonitrile

: 41253-21-8
sodium triazole

: 17201-43-3
4-cyanobenzyl bromide

: 112809-51-5
letrozol

Conditions

Conditions	Yield
Stage #1: sodium triazole; 4-cyanobenzyl bromide With potassium tert-butylate In N,N-dimethyl-formamide at -5 - 5℃; for 2.5h; Stage #2: 4-fluorobenzonitrile In N,N-dimethyl-formamide at -5 - 5℃; for 2.5h; Product distribution / selectivity;	85%
Stage #1: sodium triazole; 4-cyanobenzyl bromide In N,N-dimethyl-formamide at -10 - 0℃; for 1h; Stage #2: 4-fluorobenzonitrile With sodium hexamethyldisilazane In tetrahydrofuran; N,N-dimethyl-formamide at -10 - -5℃; Product distribution / selectivity;
Stage #1: sodium triazole; 4-cyanobenzyl bromide In ISOPROPYLAMIDE at -15 - 0℃; for 2.5h; Stage #2: 4-fluorobenzonitrile With sodium hexamethyldisilazane In tetrahydrofuran; ISOPROPYLAMIDE at -8 - 0℃; for 1h; Product distribution / selectivity;

...Expand

: C40H28ClN10Ru(1+)*BF4(1-)

: 603-35-0
triphenylphosphine

A: C41H32ClN5PRu(1+)*BF4(1-)

B: 112809-51-5
letrozol

Conditions

Conditions	Yield
In dichloromethane at 20℃; for 48h;	A 75% B n/a

...Expand

: 288-88-0
1,2,4-Triazole

: 112809-57-1
4-(alpha-chloro-4'-cyanobenzyl)-benzonitrile

: 112809-51-5
letrozol

Conditions

Conditions	Yield
With potassium carbonate In N,N-dimethyl-formamide; toluene at 60 - 80℃; for 4h;	74.4%

Raw Materials

288-88-0

Total:323 Page 1 of 9 1 2 3 4 5 6 …9 Next>>

Post a RFQ

Cas No.:

Product Name:

Quantity:

Email:

Company name:

Valid Period:

Detailed Requirements:

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

What can I do for you?
Get Best Price

Get Best Price for 112809-51-5

Specification

1. Introduction of Letrozole
Letrozole is one kind of white to off-whitecrystalline powder. The IUPAC Name of this chemical is 4-[(4-cyanophenyl)-(1,2,4-triazol-1-yl)methyl]benzonitrile. Letrozole belongs to Anti-Cancer;Pharmaceutical material and intermeidates;Active Pharmaceutical Ingredients;Letrozole;Antineoplastic;All Inhibitors;anti-neoplastic;Inhibitors;Intermediates & Fine Chemicals;Pharmaceuticals;API's;APIs;Antibiotics;Aromatics;Heterocycles.

Besides, its Classification Code is Antineoplastic; Antineoplastic agents; Aromatase Inhibitors; Enzyme inhibitors. In addition, Letrozole is freely soluble in dichloromethane, slightly soluble in ethanol, and practically insoluble in water.

2. Properties of Letrozole
Physical properties about Letrozole are:
(1)Molecular Weight: 285.30274 g/mol; (2)Molecular Formula: C₁₇H₁₁N₅; (3)XLogP3-AA: 2.7; (4)H-Bond Donor: 0; (5)H-Bond Acceptor: 4.

3. Structure Descriptors of Letrozole
(1)InChI: InChI=1S/C17H11N5/c18-9-13-1-5-15(6-2-13)17(22-12-20-11-21-22)16-7-3-14(10-19)4-8-16/h1-8,11-12,17H
(2)InChIKey: HPJKCIUCZWXJDR-UHFFFAOYSA-N
(3)Canonical SMILES: C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3
(4)Smiles: n1(C(c2ccc(cc2)C#N)c2ccc(cc2)C#N)ncnc1

4. Uses of Letrozole
Letrozole (INN, trade name Femara) is an oral non-steroidal aromatase inhibitor that has been introduced for the adjuvant treatment of hormonally-responsive breast cancer. Letrozole is approved by the United States Food and Drug Administration (FDA) for the treatment of local or metastatic breast cancer that is hormone receptor positive or has an unknown receptor status in postmenopausal women. Side effects include signs and symptoms of hypoestrogenism. There is concern that long term use may lead to osteoporosis, which is why prescriptions of Letrozole are often accompanied by prescriptions of osteoporosis-fighting medications such as bisphosphonates.

Estrogens are produced by the conversion of androgens through the activity of the aromatase enzyme. Letrozole blocks production of estrogens in this way by competitive, reversible binding to the heme of its cytochrome P450 unit. The action is specific, and letrozole does not reduce production of mineralo- or corticosteroids. In contrast, the antiestrogenic action of tamoxifen, the major medical therapy prior to the arrival of aromatase inhibitors, is due to its interfering with the estrogen receptor, rather than inhibiting estrogen production.